Gilead Sciences Forecast, price target & analysts
$166.89
0.41%
Nasdaq, Nov 06, 04:29 pm EST.
Closed.
Index
Industry
Gilead Sciences Target price 2026 - Analyst rating & recommendation
Powered by
Gilead Sciences Classifications & Recommendation
Buy
83%
Hold
17%
Gilead Sciences Price Target
| Target Price | $168.30 |
| Price | $166.89 |
| Potential | 0.84% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Gilead Sciences 2027 . The average Gilead Sciences target price is $168.30. This is 0.84% higher than the current stock price. The highest price target is $193.20 15.76% , the lowest is $127.26 23.75% . | |
| A rating was issued by 36 analysts: 30 Analysts recommend Gilead Sciences to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2027 of 0.84% . Most analysts recommend the Gilead Sciences stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
30 Analysts have issued a sales forecast Gilead Sciences 2026 . The average Gilead Sciences sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
31 Gilead Sciences Analysts have issued a net profit forecast 2026. The average Gilead Sciences net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
Gilead Sciences...
Current Gilead Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Oct 30 2026 |
| Needham |
Buy
➜
Buy
|
Unchanged | Oct 30 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 30 2026 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Oct 30 2026 |
| Scotiabank |
Sector Outperform
➜
Sector Outperform
|
Unchanged | Oct 30 2026 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 30 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Oct 30 2026 |
|
Unchanged
Needham:
Buy
➜
Buy
|
Oct 30 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 30 2026 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Oct 30 2026 |
|
Unchanged
Scotiabank:
Sector Outperform
➜
Sector Outperform
|
Oct 30 2026 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 30 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
